RALA and Hyperbilirubinemia: In line with this, Kozal et al. reported a higher number of cases of severe hyperbilirubinemia when unboosted ATV (300 mg BID) was co-administered with RAL (400 mg BID) compared to ATV 300 mg boosted with low doses of ritonavir (RTV) in combination with tenofovir 300 mg/emtricitabine 200 mg32.